UNSPSC 51432605: Naftopidil

This classification denotes an antiplatelet agent and alpha-adrenergic blocking agent with the molecular formula C24H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9PHW59SFN, chemically known as 1-pioerazineethanol, 4-(2-methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)- but generally known as naftopidil, which bears US NIH Compound Identifier 4418. European Medicines Agency schedules Naftopidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09132MIG.

UNSPSC 51432605 Naftopidil is a Commodity code covering pharmaceutical products supplied to state and local government health and emergency-response programs. State and local procurement under this code focuses on acquiring specific generic medications and pharmaceutical compounds for emergency medical services, public health agencies, and multi-state purchasing cooperatives. Recent solicitations show demand for individual medication line items — epinephrine, labetalol, adenosine, and diltiazem — supplied to emergency responders, as well as broader generic pharmaceutical and over-the-counter product portfolios distributed across multiple state and local facilities through authorized wholesaler networks. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and regional cooperative purchasing alliances spanning multiple states. The City of Tampa's fire rescue program and the Texas Health and Human Services Commission are recent buyers; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, coordinates demand across participating state and local government entities.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's reach extending to Oregon and other participating jurisdictions. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications with a due date of April 8, 2026, seeking four specific medication line items (370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials) with a nine-month minimum expiration date and ten-day delivery requirement; the estimated contract value was $40,000.00, with a one-year term and optional renewals. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026, and a two-year initial contract term. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory state-level procurement planning ahead of a formal RFP.